WuXi Biologics
https://www.wuxibiologics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From WuXi Biologics
Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group
Starting off with MSD as an anchor partner, Aurobindo plans to eventually spar with the likes of WuXi and Lonza while building scale for its biologics CDMO business. Meanwhile, EMA approval for a greenfield project in China and an US FDA nod for Ryzneuta, licensed from Yifan’s Evive Biotech, signal a boost.
Merck As Anchor, Scale As Lever, Aurobindo Looks To Spar With Lonza, WuXi Group
Starting off with MSD as an anchor partner, Aurobindo plans to eventually spar with the likes of WuXi and Lonza while building scale for its biologics CDMO business. Meanwhile, EMA approval for a greenfield project in China and an US FDA nod for Ryzneuta, licensed from Yifan’s Evive Biotech, signal a boost
Asia Deal Watch: Maruho Licenses Rights In Japan To GI Innovation’s Allergy Candidate
Plus deals involving BioLineRx/GloriaBio, Healios/Athersys, Aurobindo/Hilleman, Lupin/Menarini, GC Biopharma/Immetas, CanariaBio, Specialised Therapeutics, TaiGen/Y.S.P., Nippon/Kayaku/Adlai Nortye, WuXi/PharmaEssentia, Evommune/Maruho and Ono/Adimab.
Singapore: A Country Punching Above Its Weight
With strong government support over the past two decades, the Singaporean life sciences industry has matured. Initially known as a manufacturing hub, Singapore’s innovation ecosystem is now thriving, but the challenge is to cultivate commercialization power.
Company Information
- Industry
- Contract Research Organization-CRO
- Pharmaceuticals
- Services
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice